Khalid M. Dousa

Dr. Khalid M. Dousa

Louis Stokes Cleveland VA Medical Center and Case Western Reserve University, Cleveland, OH, USA
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 July 2020 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
KDKhalid M. Dousa
Khalid M. Dousa
SKSebastian G. Kurz
Sebastian G. Kurz
MTMagdalena A. Taracila
Magdalena A. Taracila
TBTracey Bonfield
Tracey Bonfield
CBChristopher R. Bethel
Christopher R. Bethel
Robert BonomoRobert Bonomo
Robert Bonomo
Mycobacterium abscessus is a highly drug-resistant nontuberculous mycobacterium (NTM). Efforts to discover new treatments for M. abscessus infections are accelerating, with a focus on cell wall synthesis proteins ( M. abscessus l , d -transpeptidases 1 to 5 [Ldt Mab1 to Ldt Mab5 ] and d , d -carboxypeptidase) that are targeted by β-lactam antibiotics.

22 February 2022 in mBio
Verified
Journal Article
Closed access
KDKhalid M. Dousa
Khalid M. Dousa
DNDavid C. Nguyen
David C. Nguyen
SKSebastian G. Kurz
Sebastian G. Kurz
MTMagdalena A. Taracila
Magdalena A. Taracila
CBChristopher R. Bethel
Christopher R. Bethel
Robert BonomoRobert Bonomo
Robert Bonomo
Durlobactam (DUR) is a potent inhibitor of Bla Mab and provides protection of amoxicillin and imipenem against hydrolysis. DUR has intrinsic activity and forms stable acyl-enzyme complexes with Ldt Mab2 and Ldt Mab4 . The ability of DUR to protect amoxicillin and imipenem against Bla Mab and its intrinsic activity along with the dual β-lactam target redundancy can explain the rationale behind the potent activity of this combination.

19 December 2018 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
KDKhalid M. Dousa
Khalid M. Dousa
AHAbdelrahman Hamad
Abdelrahman Hamad
MAMohamed Albirair
Mohamed Albirair
HSHussam Al Soub
Hussam Al Soub
AEAbdel-Naser Elzouki
Abdel-Naser Elzouki
JJJohn L Johnson
John L Johnson
Background: Persons with diabetes mellitus (DM) have a 3-fold increased risk of tuberculosis (TB). Atypical radiographic findings and differences in bacteriologic response during anti-TB treatment have been reported in earlier studies; however, the findings have varied. We evaluated the effect of DM on manifestations and response to treatment in adults with pulmonary TB in Qatar.Methods: The impact of DM on the clinical and radiographic presentations of pulmonary TB and bacteriologic response during anti-TB treatment was evaluated between January 2007 and December 2011, comparing patients with and without DM. This is a retrospective unmatched case-control study conducted at a large national hospital. Cases and controls were randomly selected from patients diagnosed with pulmonary TB over a 5-year period. Sputum culture conversion was assessed after 2 months of anti-TB treatment.Results: Clinical symptoms were similar between patients with and without DM. Patients with DM had a higher initial sputum acid-fast bacillus (AFB) smear grade and were less likely to have cavitary lesions on initial chest radiographs than patients without DM. Of 134 adults with DM and TB, 71 (53%) remained sputum culture positive after 2 months of anti-TB treatment, compared with 36 (27%) patients without DM.Conclusions: DM was associated with atypical radiographic findings and delayed sputum culture conversion at 2 months in adults with pulmonary TB in Qatar. Increased health education of patients with DM about symptoms of TB, low thresholds for evaluation for active TB, and close monitoring of bacteriologic response to treatment among patients with TB and DM are warranted.

1 June 2023 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
BABayan Alahmdi
Bayan Alahmdi
KDKhalid M. Dousa
Khalid M. Dousa
SKSebastian G Kurz
Sebastian G Kurz
AKAndrew Kaufman
Andrew Kaufman
RBRobert A Bonomo
Robert A Bonomo
STSarah Taimur
Sarah Taimur
Macrolide resistance has rendered the treatment of Mycobacterium abscessus extremely difficult and is fueling a crisis. Recently, there has been dramatically increased incidence of infections by M abscessus. Select dual β-lactam combinations have shown promising in vitro results. Herein, we present a patient whose M abscessus infection cured using dual β-lactams as part of multidrug regimen.

13 February 2025 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
ESEunjeong Shin
Eunjeong Shin
KDKhalid M. Dousa
Khalid M. Dousa
MTMagdalena A. Taracila
Magdalena A. Taracila
CBChristopher R. Bethel
Christopher R. Bethel
MNMary Nantongo
Mary Nantongo
Robert BonomoRobert Bonomo
Robert Bonomo
Mycobacterium abscessus ( Mab ) presents significant clinical challenges. This study evaluated the synergistic effects of a β-lactam and β-lactamase inhibitor combination against Mab and explored the underlying mechanisms. Synergy was assessed through MIC tests and time-kill studies, and binding affinities of nine β-lactams and BLIs to eight target receptors (L,D-transpeptidases [LDT] 1–5, D,D-carboxypeptidase, penicillin-binding protein [PBP] B, and PBP-lipo) were assessed using mass spectrometry and kinetic studies. Thermal stability and morphological changes were determined. Imipenem demonstrated high binding affinity to LDTs and PBPs, with extremely low inhibition constants ( K i , app ; ≤0.002 mg/L for LDT1−2, ≤0.6 mg/L for PBPs), while cephalosporins, sulopenem, tebipenem, and amoxicillin exhibited moderate to low binding affinity. Durlobactam inactivated Bla Mab and LDT/PBPs more potently than avibactam. The K i,app s of durlobactam for PBP B, PBP-lipo, and LDT2 were below clinically achievable unbound concentrations, while avibactam’s K i,app for LDT/PBPs exceeded the clinical concentrations. Single β-lactam treatments resulted in minimal killing (~1 log 10 reduction). Although avibactam yielded no effect, combinations with avibactam showed a significant reduction (~4 log 10 CFU/mL). Durlobactam alone showed ~2 log 10 reduction, and when combined with imipenem or two β-lactams, durlobactam achieved near-eradication of Mab , surpassing the current therapy (amikacin + clarithromycin + imipenem/cefoxitin). Inactivation of PBP-lipo by sulopenem, imipenem, durlobactam, and amoxicillin (with avibactam) led to morphological changes, showing filaments. This study demonstrates the mechanistic basis of combinations therapy, particularly imipenem + durlobactam, in overcoming β-lactam resistance in Mab .

1 July 2018 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
KDKhalid M. Dousa
Khalid M. Dousa
ABAhmed Babiker
Ahmed Babiker
DADaniel Van Aartsen
Daniel Van Aartsen
NSNeel Shah
Neel Shah
RBRobert A Bonomo
Robert A Bonomo
MSMarion J Skalweit
Marion J Skalweit
Ibrutinib is an irreversible inhibitor of Bruton’s tyrosine kinase approved for the treatment of B-cell malignancies. There is growing concern about the risk of opportunistic infections following ibrutinib therapy. Herein, we describe the first case of Mycobacterium chelonae skin and soft tissue infection in a patient receiving ibrutinib and recount the challenges in treating this infection.